British pharmaceutical manufacturer moves to Denmark: We'll find the best workforce here

Denmark's position in the world market for peptide-based pharmaceutical development now causes a British biotech firm to relocate its entire management and development lab to the country. The goal is effective growth, and the firm has already made a deal with a top-ten pharma company.

SB3000 CEO Zsolt Lavotha Photo: Zsolt Lavotha, adm. direktør, SB3000

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles